Orthofix Medical Inc.

OFIX • Medical - Devices

$9.29

▼ -0.02 (-0.21%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$380.02M

Growth

6.6%

Cash Flow

0/5

Trend

Negative

Evidence

Manageable debt level · 0.51Healthy liquidity · 2.45Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$9.29

Change-0.21%

Shares Out40.91M

Market Cap$380.02M

Enterprise Value$510.83M

52W Range8.85 - 16.99

Beta0.71

P/E-6.16

P/S0.46

P/B0.89

P/FCF-10.34

EV/Sales0.61

Price$9.29

Change-0.21%

Shares Out40.91M

Market Cap$380.02M

Enterprise Value$510.83M

52W Range8.85 - 16.99

Beta0.71

P/E-6.16

P/S0.46

P/B0.89

P/FCF-10.34

EV/Sales0.61

EV/EBITDA6.08

EV/FCF-13.90

Earnings Yield-16.24%

FCF Yield-9.67%

Dividend Yield0.00%

Gross Margin67.09%

Oper. Margin-8.33%

Profit Margin-11.21%

Debt/Eq0.51

Current Ratio2.45

Quick Ratio2.24

Revenue 5Y6.55%

Target$13.40

Target Upside44.24%

Target Median$13.00

Target Range12.00 - 15.00

Volume472.22K

Avg Volume411.84K

EPS Surprise0.16

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

74/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

94/100

Why this score▼

Manageable debt level · 0.51Healthy liquidity · 2.45Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

OFIX

Analyst sentiment

Based on 17 analyst votes · 2026-09-05

74/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$12.00

Mean

$14.40

Median

$14.00

High

$18.00

Company Overview

IPO: 4/24/1992

Industry: Medical - Devices

P/B i: 0.89

Debt / Equity i: 0.51

Operating Margin: -8.33%

Net Margin: -11.21%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.51

Current Ratio: 2.45

Quick Ratio: 2.24

Status: Good

Insider Transactions

Recent executive and insider activity

McPherron Aviva

Transaction: 06/18/2026

SELL

Change

-3,670

Price

$9.38

Filing

06/22/2026

Type

SELL

Paolucci Michael E

Transaction: 06/10/2026

BUY

Change

+14,965

Price

Not reported

Filing

06/12/2026

Type

BUY

Maniar Shweta

Transaction: 06/10/2026

BUY

Change

+14,965

Price

Not reported

Filing

06/12/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
McPherron Aviva	SELL	-3,670	$9.38	06/18/2026	06/22/2026
Paolucci Michael E	BUY	+14,965	Not reported	06/10/2026	06/12/2026
Maniar Shweta	BUY	+14,965	Not reported	06/10/2026	06/12/2026
BURRIS WAYNE	BUY	+14,965	Not reported	06/10/2026	06/12/2026
HENNEMAN JOHN B III	BUY	+14,965	Not reported	06/10/2026	06/12/2026
CAPPS VICKIE L	BUY	+14,965	Not reported	06/10/2026	06/12/2026
Finegan Michael	BUY	+20,721	Not reported	06/10/2026	06/12/2026
Hannon Jason	BUY	+14,965	Not reported	06/10/2026	06/12/2026
Kummeth Charles R.	BUY	+14,965	Not reported	06/10/2026	06/12/2026
Bazaar Alan Lee	BUY	+14,965	Not reported	06/10/2026	06/12/2026
Juniper Investment Company, LLC	BUY	+242,000	$10.70	05/22/2026	05/29/2026
Juniper Investment Company, LLC	OTHER	0	Not reported	05/21/2026	05/29/2026
HENNEMAN JOHN B III	BUY	+5,000	$12.26	05/07/2026	05/08/2026
Engine Capital Management, LP	BUY	+1,808	$12.20	05/07/2026	05/07/2026
Engine Capital Management, LP	BUY	+3,792	$12.23	05/06/2026	05/07/2026
Engine Capital Management, LP	BUY	+2,911	$11.99	05/05/2026	05/07/2026
Cedron Jorge Andres	SELL	-3,743	$12.82	04/16/2026	04/20/2026
Vitale Lucas	SELL	-4,269	$11.92	03/17/2026	03/19/2026
CAPPS VICKIE L	BUY	+100	$12.44	03/10/2026	03/10/2026
CAPPS VICKIE L	BUY	+2,500	$12.48	03/09/2026	03/10/2026

About the Company

Orthofix Medical Inc.

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Source - link

Peers

ABSI AVNS BFLY DRIO ESPR LAB MLTX PACB SIBN VREX

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

Orthofix Medical NASDAQ: OFIX executives said the company's updated outlook reflects the restoration of bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.

MarketBeat

Orthofix Medical Q2 Earnings Call Highlights

Orthofix Medical NASDAQ: OFIX reported second-quarter results that management said reflected improving operating trends across several businesses, while continued weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, disciplined investment and profitable growth rather than pursuing revenue growth at any cost.

MarketBeat

Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript

Seeking Alpha

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Zacks Investment Research

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

Orthofix (OFIX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.13 per share a year ago.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-05	-0.68	-0.52	0.16
2026-02-24	-0.19	-0.0555	0.1345
2025-11-04	0.12	0.2	0.08
2025-08-05	0.04	0.13	0.09
2025-05-06	-0.17	-0.08	0.09
2025-02-25	0.06	0.02	-0.04
2024-11-07	-0.14	0.07	0.21
2024-08-06	-0.13	0.05	0.18
2024-05-07	-0.32	-0.46	-0.14
2024-03-05	-0.14	-0.1	0.04
2023-11-08	-0.22	0.07	0.29
2023-08-08	-0.67	0.02	0.69